BNNY: This Will Be Ugly

BNNY remains on the Hedgeye Best Ideas list as a Short.


Annie’s is reporting 1QF15 earnings on August 7th AMC.


Trading at 33x P/E (NTM), BNNY continues to be overvalued and is likely to contract further as we believe the company will disappoint on Thursday and guide lower for the remainder of the fiscal year.


Over the long run, the Annie’s brand and continued growth of organics should power above average sales growth, but earnings will remain elusive.  Importantly, BNNY will not generate any operating profit this quarter.  The competitive pressures in the organic space, specifically in the Mac ‘N’ Cheese segment, will not abate anytime soon.


Earnings estimates have moved slightly lower during the quarter, as the organic segment continues to see slower trends.  Depending on how well the company is able to manage SG&A, we believe earnings will come in around ($0.05) for the quarter.  This is $0.02 below consensus, but it wouldn’t surprise us if the company is able to manage expenses to limit the damage in the quarter.


Our model generates lower sales than the Street, as well as lower gross margins and SG&A margins.  We’re expecting sales growth of +3% in the Meals segment, which would imply a slowdown from recent trends in the category, reflecting the recent deceleration in consumption and the UNFI deloading.


BNNY: This Will Be Ugly - 1


Following the release, we expect the FY15 consensus EPS estimate of $0.90 to be revised lower by $0.10-0.20. 


The risk to staying short is an outright sale of the company, but we don’t see this happening any time soon!


The table below outlines our risk/reward profile for the company.


BNNY: This Will Be Ugly - 2


Howard Penney

Managing Director


Matt Hedrick



Fred Masotta



GOLD: A Deep Dive on What’s Next with a Top Commodities Strategist

“If you saved in gold over the past 20 to 25 years rather than any currency anywhere in the world, gold has outperformed all these currencies,” says Stefan Wieler, Vice President of Goldmoney in this edition of Real Conversations.

read more

Exact Sciences Up +24% This Week... What's Next? | $EXAS

We remain long Exact Sciences in the Hedgeye Healthcare Position Monitor.

read more

Inside the Atlanta Fed's Flawed GDP Tracker

"The Atlanta Fed’s GDPNowcast model, while useful at amalgamating investor consensus on one singular GDP estimate for any given quarter, is certainly not the end-all-be-all of forecasting U.S. GDP," writes Hedgeye Senior Macro analyst Darius Dale.

read more

Cartoon of the Day: Acrophobia

"Most people who are making a ton of money right now are focused on growth companies seeing accelerations," Hedgeye CEO Keith McCullough wrote in today's Early Look. "That’s what happens in Quad 1."

read more

People's Bank of China Spins China’s Bad-Loan Data

PBoC Deputy Governor Yi says China's non-performing loan problem has “pretty much stabilized." "Yi is spinning. China’s bad-debt problem remains serious," write Benn Steil and Emma Smith, Council on Foreign Relations.

read more

UnderArmour: 'I Am Much More Bearish Than I Was 3 Hours Ago'

“The consumer has a short memory.” Yes, Plank actually said this," writes Hedgeye Retail analyst Brian McGough. "Last time I heard such arrogance was Ron Johnson."

read more

Buffalo Wild Wings: Complacency & Lack of Leadership (by Howard Penney)

"Buffalo Wild Wings has been plagued by complacency and a continued lack of adequate leadership," writes Hedgeye Restaurants analyst Howard Penney.

read more

Todd Jordan on Las Vegas Sands Earnings

"The quarter actually beat lowered expectations. Overall, the mass segment performed well although base mass lagging is a concern," writes Hedgeye Gaming, Lodging & Leisure analyst Todd Jordan on Las Vegas Sands.

read more

An Update on Defense Spending by Lt. Gen Emo Gardner

"Congress' FY17 omnibus appropriation will fully fund the Pentagon's original budget request plus $15B of its $30B supplemental request," writes Hedgeye Potomac Defense Policy analyst Lt. Gen Emerson "Emo" Gardner USMC Ret.

read more

Got Process? Zero Hedge Sells Fear, Not Truth

Fear sells. Always has. Look no further than Zero Hedge.

read more

REPLAY: Review of $EXAS Earnings Call (A Hedgeye Best Idea Long)

Our Healthcare Team made a monster call to be long EXAS - hear their updated thoughts.

read more

Capital Brief: 5 Things to Watch Right Now In Washington

Here's a quick look at some key issues investors should keep an eye on from Hedgeye's JT Taylor and our team of Washington Policy analysts in D.C.

read more